US2021220453A1PendingUtilityA1

Chagas Antigens and Antibodies and Compositions, Methods and Uses Thereof

61
Assignee: PEPTCELL LTDPriority: Apr 14, 2016Filed: Apr 3, 2021Published: Jul 22, 2021
Est. expiryApr 14, 2036(~9.7 yrs left)· nominal 20-yr term from priority
Inventors:Olga Pleguezuelos MateoWilson Romero Caparros-WanderleyGregory Alan Stoloff
Y02A50/30A61K 2039/57A61K 2039/55566A61P 33/02C07K 14/44A61K 39/005A61K 2039/575A61P 37/04A61K 2039/545
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising such Trypanosoma antigens, methods and uses for such Trypanosoma antigens and immunogenic compositions for treating a Trypanosoma-based disease.

Claims

exact text as granted — not AI-modified
1 . A trypanosome antigen consisting of the amino acid sequence of SEQ ID NO: 9. 
     
     
         2 . An immunogenic composition comprising one or more trypanosome antigens and one or more adjuvants, wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 9, or a peptide having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 9 or fragments thereof, wherein a fragment is at least 7 and at most 33 amino acids in length, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 9. 
     
     
         3 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 9. 
     
     
         4 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6. 
     
     
         5 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 5, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 5, or a peptide of at most 39 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 5. 
     
     
         6 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 5, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 5, or a peptide of at most 39 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 5 and the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6. 
     
     
         7 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6 and the amino acid sequence of SEQ ID NO: 9, respectively. 
     
     
         8 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         9 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         10 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         11 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         12 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 5, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 5, or a peptide of at most 39 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         13 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of SEQ ID NO: 11, respectively. 
     
     
         14 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 5, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 5, or a peptide of at most 39 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 6, or a peptide of at most 34 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         15 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of SEQ ID NO: 11, respectively. 
     
     
         16 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         17 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of SEQ ID NO: 11, respectively. 
     
     
         18 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens further comprise the amino acid sequence of SEQ ID NO: 2, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 2, or a peptide of at most 30 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 7, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 7, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 8, or a peptide of at most 35 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 8, and the amino acid sequence of SEQ ID NO: 11, or a peptide having at least 80% amino acid identity to the amino acid sequence of SEQ ID NO: 11, or a peptide of at most 33 amino acids and having at least 7 contiguous amino acids from the amino acid sequence of SEQ ID NO: 11. 
     
     
         19 . The immunogenic composition according to  claim 3 , wherein the one or more trypanosome antigens comprise the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of SEQ ID NO: 11, respectively. 
     
     
         20 . The immunogenic composition according to  claim 2 , wherein the one or more trypanosome antigens are each present in an amount of between about 1 mg to about 1,000 mg.

Join the waitlist — get patent alerts

Track US2021220453A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.